Adding Hydroxyurea to Imatinib is Effective in Patients with Chronic My-elogenous Leukemia Resistant to Imatinib Alone
Roberto Latagliata*, Massimo Breccia, Ida Carmosino, Paola Volpicelli, Rosa De Cuia, Laura Napoleone, Federico Vozella, Franco Mandelli , Giuliana Alimena
Dipartimento di Biotecnologie Cellulari ed Ematologia, University “La Sapienza” of Rome, Italy
From 11/02 to 11/03, 11 patients in chronic phase (6 males and 5 females, median age 52.9 years, range 29.9-67.9 years) with persistance of >66% Ph+ cells after both standard and increased dose of Imatinib alone, were considered resistant and added Hydroxyurea (HU) to Imatinib. Seven patients were pretreated with IFN before Imatinib, median times from diagnosis and from Imatinib treatment to HU addition were 51 months (range 23-151) and 13 months (range 9-31), respectively. Four patients achieved. Complete Cytogenetic Response (CCR) after 3, 7, 12 and 32 months and 2 patients achieved a Major Cytogenetic Response (MCR) after 3 and 7 months, the remaining 5 patients were resistant, with persistence of Ph+ 100%. One patient in CCR achieved also Complete Molecular Response (CMolR) and is still responsive after 23 months. The other 3 patients in CCR as well as the 2 patients in MCR relapsed after 4, 4, 4, 10 and 12 months. In conclusion, this study provides the 1st in vivo evidence of an additive activity of HU and Imatinib; this association seems capable to induce cytogenetic response in at least one third of patients resistant to Imatinib alone, with minimal toxicity: a longer follow-up and a comparison with other associations is needed to evaluate the quality and duration of such response.
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
* Address correspondence to this author at the Cattedra di Ematologia, Via Benevento 6-00161, Rome, Italy; Tel: 0039-06-857951; Fax: 0039-06-44241984; E-mail: email@example.com